Search | Page 17 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. MDS Progression to AML: What Patients Need to Know

    ... myeloid leukemia (AML), which does not respond well to chemotherapy . AML is a bone marrow malignancy where the marrow is ...

    LMS Item last updated 06/10/2016 - 1:24pm.

  2. Nonmyeloablative Allogeneic Transplant (Mini-allo)

    ... Cell Lymphoma (any Stage - must have received induction chemotherapy ) Multiple Myeloma (10% residual plasmacytosis following anthracycline-based chemotherapy or residual disease following autologous transplant) ...

    Clinical Trial last updated 04/28/2016 - 2:13pm.

  3. Study of FF-10501-01 in Patients With Relapsed or Refractory Hematological Malignancies

    ... therapies At least 3 weeks beyond the last chemotherapy , targeted anticancer agent, major surgery or experimental ...

    Clinical Trial last updated 06/06/2016 - 10:47am.

  4. Lenalidomide and Rituximab in Subjects With Previously Untreated Indolent Non-Hodgkin's Lymphoma

    ... is effective as a single agent and in combination with chemotherapy for indolent Non-Hodgkin's Lymphoma. The purpose of this ...

    Clinical Trial last updated 06/06/2016 - 10:17am.

  5. UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep

    ... hematologic malignancies not curable by conventional chemotherapy . Responses to conventional treatment range from zero to 30% ... lymphoma, Hodgkin lymphoma and multiple myeloma with chemotherapy sensitive disease who are ineligible for an autologous transplant. ...

    Clinical Trial last updated 04/29/2016 - 10:06am.

  6. A Study of E6201 for the Treatment of Advanced Hematologic Malignancies With FLT3 Mutation (AML)

    ... FLT3+ AML and not eligible for standard induction chemotherapy or FLT3+ high-risk MDS/CMML (defined as ≥ 10% ... to prior therapy At least 4 weeks beyond the last chemotherapy, (or ≥ 2 weeks or ≥ 2 5 half- lives for targeted agents, ...

    Clinical Trial last updated 05/09/2016 - 4:09pm.

  7. Risk of developing MDS and AML after radiation treatment for breast cancer

    ... increases in patients who receive multiple rounds of chemotherapy and radiation therapy, and also in those who undergo stem cell ... lymphoma. Read more about t-MDS Radiation and chemotherapy are key components of cancer treatments and carry an increased ...

    Research Review last updated 05/02/2016 - 9:32am.

  8. Panobinostat With Fludarabine and Cytarabine for Treatment of Children With Acute Myeloid Leukemia or Myelodysplastic Syndrome

    ... multiple mechanisms. Panobinostat belongs to a class of chemotherapy drugs called "histone deacetylase (HDAC) inhibitors." HDAC ... causes them to die. Fludarabine and cytarabine are chemotherapy drugs that are commonly used to treat pediatric patients with ...

    Clinical Trial last updated 04/29/2016 - 10:11am.

  9. Hematopoietic Stem Cell Transplantation in the Treatment of Infant Leukemia

    ... Purpose:  RATIONALE: Giving chemotherapy , such as busulfan, fludarabine , and melphalan, before ... This phase II trial is studying how well combination chemotherapy followed by a donor umbilical cord blood transplant works ...

    Clinical Trial last updated 04/29/2016 - 9:56am.

  10. Sirolimus and Azacitidine in Treating Patients With High Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia That is Recurrent or Not Eligible for Intensive Chemotherapy

    ... of the enzymes needed for cell growth. Drugs used in chemotherapy , such as azacitidine, work in different ways to stop the ...

    Clinical Trial last updated 04/28/2016 - 1:13pm.